BNP Paribas Knock-Out 6MK/ DE000PD2NU20 /
2024-04-25 9:42:05 PM | Chg.- | Bid8:25:04 AM | Ask8:25:04 AM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
4.82EUR | - | 4.82 Bid Size: 6,000 |
4.84 Ask Size: 6,000 |
MERCK CO. D... | 79.1848 - | 2078-12-31 | Call |
GlobeNewswire
04-25
Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes ...
GlobeNewswire
03-06
IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Can...
GlobeNewswire
03-04
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Ger...
GlobeNewswire
2023-12-21
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
2023-12-19
Unnatural Products, Inc. Announces $32 Million in Series A Funding Led by Merck Global Health Innova...
GlobeNewswire
2023-12-14
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development an...
GlobeNewswire
2023-12-12
C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degr...
GlobeNewswire
2023-12-05
HiberCell, Inc. Announces Clinical Collaboration with Merck to Evaluate HC-7366, an Activator of ISR...
GlobeNewswire
2023-12-04
Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule
GlobeNewswire
2023-11-13
Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
GlobeNewswire
2023-10-17
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA